Table E1.

Simulation results, societal perspective

Analysis	Cost (US $)	Anaphylaxis events	Anaphylaxis hospitalization	Anaphylaxis fatality	COVID-19 hospitalization	COVID-19 fatality	Total hospitalizations	Total fatalities	NMB	C/E	ICER	Population estimate
Base case (per patient)												300,000,000
Universal vaccination	$17	0.000998056	0.00022	0.0000033	9.00 × 10−05	3.00 × 10−05	0.00031	3.33 × 10−05	$9,999,650	$17	—
Risk stratify	$19	4.74 × 10−05	0.00001045	1.57 × 10−07	0.0001755	5.85 × 10−05	0.00018595	5.87 × 10−05	$9,999,395	$19	−$65,518
Universal vs risk stratify
Per patient	−$2	0.000950649	0.00020955	3.14 × 10−06	−8.55 × 10−05	−2.85× 10−05	0.00012405	−2.54× 10−05	$255
Per 300 million persons	−$498,401,457	285,195	62,865	943	−25,650	−8,550	37,215	−7,607	$76,568,934,350

C/E, Cost-effectiveness.